Advertisement

Search Results

Advertisement



Your search for Sara M. Tolaney, MD, MPH matches 12 pages

Showing 1 - 12


breast cancer
immunotherapy

Sara M. Tolaney, MD, MPH, on HER2-Positive Breast Cancer: ATEMPT Trial on T-DM1 vs Paclitaxel Plus Trastuzumab

Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute, discusses phase II findings on patients receiving T-DM1 monotherapy as adjuvant treatment for stage I HER2-positive breast cancer, a regimen associated with few recurrences in the study population (Abstract GS1-05).

breast cancer

Abemaciclib Benefits Patients With HER2-Positive Breast Cancer in monarcHER Trial

Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are associated with a robust benefit in patients with hormone receptor–positive, HER2-negative breast cancer, but now the monarcHER trial has confirmed their benefit in the HER2-positive population. The new findings were reported at the...

breast cancer

Follow-up of Adjuvant Paclitaxel and Trastuzumab in Small HER2-Positive Breast Tumors

As reported in the Journal of Clinical Oncology by Tolaney et al, 7-year follow-up of the phase II Adjuvant Paclitaxel and Trastuzumab trial showed that adjuvant paclitaxel and trastuzumab were associated with “excellent” outcomes in women with small, node-negative HER2-positive breast...

solid tumors

Incidence of Endocrine Dysfunction With Immune Checkpoint Inhibitors

In a systematic review and meta-analysis reported in JAMA Oncology, Barroso-Sousa et al evaluated the incidence of endocrine dysfunction in patients receiving currently approved immune checkpoint inhibitors for various advanced solid tumors. Patients who received combination therapy were found to...

sarcoma
cns cancers
lymphoma
survivorship

In Case You Missed It: Short Takes on Current Cancer Research

MOST ONCOLOGISTS are familiar with the findings of the plenary sessions featured at the 2017 ASCO Annual Meeting, with topics ranging from the duration of adjuvant oxaliplatin-based therapy in stage III colon cancer to patient-reported outcomes for symptom monitoring during routine cancer...

breast cancer

Abemaciclib Plus Fulvestrant Delays Breast Cancer Progression in MONARCH 2

In the treatment of metastatic estrogen receptor–positive breast cancer, a highly significant 45% reduction in progression was achieved with abemaciclib, combined with fulvestrant (Faslodex), in the global phase III MONARCH 2 trial, reported at the 2017 ASCO Annual Meeting by George W. Sledge, MD,...

breast cancer

Results From MONALEESA-2: Are All CDK4/6 Inhibitors Equal?

Hormone receptor–positive breast cancer is the most common subtype of breast cancer, and while endocrine therapy has long been a mainstay of therapy for these patients, treatment resistance ultimately develops. Therefore, better therapeutic approaches are needed. There are some data to suggest...

breast cancer

ASCO Guideline Addresses Controversial Areas in Adjuvant Therapy for Breast Cancer

ASCO has published an adaptation of the 2015 Cancer Care Ontario (CCO) clinical practice guideline on adjuvant chemotherapy for early-stage breast cancer.1 There were several areas of controversy that the guideline attempts to address. Should Anthracyclines Be Standard of Care? The guideline...

breast cancer

Program Co-Directors Highlight Abstracts of Interest for the Upcoming 2013 San Antonio Breast Cancer Symposium

The Co-Directors of the 2013 CTRC-AACR San Antonio Breast Cancer Symposium, which will be held December 10–14, 2013, have highlighted what they consider to be the most important abstracts to be presented at the Symposium. In a telebriefing in advance of the December meeting, C. Kent Osborne, MD,...

breast cancer

HER2-Positive Breast Cancer Patients With Small Tumors Benefit From Low-Toxicity Regimen 

There may be a benefit for treating small HER2-positive tumors—a breast cancer subset for whom treatment recommendations have not been established but for whom there is still risk of recurrence—and this can be done with little toxicity, according to a multicenter study presented at the 2013 San...

breast cancer

HER2-Positive Breast Cancer Patients With Small Tumors Benefit From Low-Toxicity Regimen

There may be a benefit for treating small HER2-positive tumors—a breast cancer subset for whom treatment recommendations have not been established but for whom there is still risk of recurrence—and this can be done with little toxicity, according to a multicenter study presented at the 2013 San...

breast cancer

High Invasive Disease-Free Survival With Adjuvant Paclitaxel and Trastuzumab in Small, Node‑Negative, HER2-Positive Breast Cancers

In a phase II study reported in The New England Journal of Medicine, Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute, and colleagues found that adjuvant paclitaxel and trastuzumab (Herceptin) was associated with high invasive disease-free survival in women with small, node-negative,...

Advertisement

Advertisement



Advertisement